The association of anticoagulant protein concentration with acute myocardial infarction in the Thrombolysis In Myocardial Infarction phase II (TIMI II) trial

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 1, 1998, Pages 53-60

  Callas, Peter W ^a,b   Tracy, Russell P ^a   Bovill, Edwin G ^a   Cannon, Christopher ^c   Thompson, Bruce ^d   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b University of Vermont   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antithrombin III; Protein C; Protein S; Thrombolytic therapy

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTICOAGULANT PROTEIN; ANTITHROMBIN III; FIBRINOGEN; PLASMINOGEN; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN DEFICIENCY; PROTEIN S DEFICIENCY;

EID: 0031884218     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008866505047     Document Type: Article

References (45)

1. Esmon C. Protein C: Biochemistry, physiology and clinical implications. Blood 1983;62:1155-1158.
2. Comp P. Clinical implications of the protein C/Protein S system. Ann NY Acad Sci 1987;509:149-155.
3. Rosenberg R. Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc 1977:36: 10-18.
4. Bertina R. Hereditary protein S deficiency. Haemostasis 1985;15:241-246.
5. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency: incidence and clinical features. Am J Med 1989; 87(Suppl 3B):34S-38S.
6. Miletich J. Laboratory diagnosis of protein C deficiency. Sem Thromb Haemos 1990;16:169-176.
7. Bovill E, Bauer K, Dickerman J, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989;73:712-717.
8. Dahlbaek B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-614.
9. Bertina R, Koeleman B, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
10. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemostas 1994;72:647 (letter).
11. Ridker P, Hennekens C, Lindpaintner K, Stampfer M, Eisenberg P, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917.
12. (TIMI) The TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA 1988;260:2849-2858.
13. (TIMI) The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1989;320:618-627.
14. Braunwald E, Knatterud G, Passamani E. Announcement of protocol change in thrombolysis in myocardial infarction trial J Am Coll Cardiol 1987;9:467 [Letter].
15. Bovill E, Terrin M, Stump D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-265.
16. Tracy R, Bovill E, Stump D, et al. Reduction of in vitro artifact during blood collection in TIMI II. Blood 1988;78 (Suppl 1):376 (Abstract).
17. Geffken D, Keating F, Kennedy M, Cornell E, Bovill E, Tracy R. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med 1994;118:1106-1109.
18. Tracy R, Bovill E. Tissue-type plasminogen activator. In: Beutler E, Lichtman M, Coller B, Kipps T, eds. Williams Hematology. New York: McGraw-Hill, 1995:L108-L109.
19. Tracy R, Bovill E. Plasminogen and alpha-2-antiplasmin. In: Beutler E, Lichtman M, Coller B, Kipps T, eds. Williams Hematology. New York: McGraw-Hill, 1995:L106.
20. Clauss A. Gerinnungs-physiologische schnell-methode zur bestimmung des fibrinogens. Acta Haematol 1957;17:237-246.
21. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985;54:684-697.
22. Howard P, Bovill E, Mann K, Tracy R. A monoclonal antibody-based immunoassay for measurement of protein C in plasma. Clin Chem 1988;34:324-330.
23. Bovill E, Landesman M, Busch S, Fregeau G, Mann K, Tracy R. Studies on the measurement of protein S in plasma. Clin Chem 1991;37:1708-1714.
24. Comp P. Laboratory evaluation of protein S status. Sem Thromb Hemos 1990;16:177-181.
25. Gensini G, Rostagno C, Abbate R, Favilla S, Mannucci P, Neri Serneri G. Increased protein C and fibrinopeptide A concentration in patients with angina. Thromb Res 1988;50: 517-525.
26. Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Hemostatic factors and incidence of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1996;93:622 (abstract).
27. Folsom A, Wu K, Shahar E, Davis C. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thrombos 1993;13:1829-1836.
28. Thompson S, Fechtrup C, Squire E, et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16: 357-362.
29. Meade T, Cooper J, Miller G, Howarth D, Stirling Y. Anti-thrombin III and arterial disease. Lancet 1991;338:850-851.
30. Amrani D. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagulation and Fibrinolysis 1990;1:443-446.
31. Robson S, Shephard E, Kirsch R. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1B, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Brit J Haematol 1994;86:322-326.
32. Dahlback B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981;78:2512-2516.
33. Walker T, Triplett D, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res 1988;51: 267-281.
34. Wolf M, Boyer-Neumann C, Leroy-Matheron C, et al. Functional assay of protein S in 70 patients with congenital and acquired disorders. Blood Coagul Fibrinolys 1991;2:705-712.
35. Bauer K, Weiss L, Sparrow D, Vokonas P, Rosenberg R. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987;80: 1527-1534.
36. Conlan M, Folsom A, Finch A, et al. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost 1994;72:551-556.
37. Henkens C, Bom V, van der Schaaf W, et al. Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Thrombos Haemostas 1995;74:1271-1275.
38. Eisenberg P, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. JACC 1986;7:1253-62.
39. Gulba P, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: Relevance for the success of therapy. Circulation 1991;83:937-944.
40. Gulba D, Daniel W, Simon R, et al. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. JACC 1990: 16:563-568.
41. Hoffman J, Michels H, Windeler J, Gunzler W. Plasma markers of thrombin activity during coronary thrombolytic therapy with saruplase or urikinase: no prediction of reinfarction. Fibrinolysis 1993;7:330-334.
42. Merlini P, Bauer K, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. JACC 1995;25:203-209.
43. Marciniak E, Gockerman J. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977;2:581-584.
44. Tracy R, Losito R, Howard P, Cushman M, Bovill E. The association of plasma lipids and vitamin K-dependent coagulation factors. In: Bray G, Ryan D, eds. Nutrition, genetics and heart disease. Vol. 6. Baton Rouge: LSU Press, 1996:29-49.
45. Hoffman C, Lawson W, Miller R, Hultin M. Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults. Arteriosclerosis Thrombosis 1994;14:1737-1740.